Mod Rheumatol
Modern Rheumatology
1439-7595
1439-7609
Springer Japan
Japan


2275302
18176779
17
10.1007/s10165-007-0017-9
Review Article


Gene therapy for arthritis

Traister
Russell S.



Hirsch
Raphael

+1-412-6925970
+1-412-6925054
raphael.hirsch@chp.edu



Division of Rheumatology, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 3705 Fifth Avenue, Pittsburgh, PA 15213 USA 

5
1
2008

2
2008

18
1
2
14
28
8
2007

9
10
2007


© Japan College of Rheumatology 2007

Arthritis is among the leading causes of disability in the developed world. There remains no cure for this disease and the current treatments are only modestly effective at slowing the disease's progression and providing symptomatic relief. The clinical effectiveness of current treatment regimens has been limited by short half-lives of the drugs and the requirement for repeated systemic administration. Utilizing gene transfer approaches for the treatment of arthritis may overcome some of the obstacles associated with current treatment strategies. The present review examines recent developments in gene therapy for arthritis. Delivery strategies, gene transfer vectors, candidate genes, and safety are also discussed.

Keywords
Rheumatoid arthritis
Gene therapy
Gene transfer
Inflammation
Cytokines

issue-copyright-statement
© Japan College of Rheumatology 2008




Introduction
1
2
3
]. Although the pathogenesis of RA is not completely understood, specific HLA-DR genes, autoantibody and immune complex production, T cell antigen-specific responses, networks of cytokine production, and a hyperplastic synovium have all been shown to play a role.
4
5
6
7
6
8
9
].
10
11
]. Gene transfer strategies have the potential to overcome some of these limitations, potentially leading to increased efficacy and decreased frequency of administration.

Gene delivery strategies
12
14
15
16
]. Systemic delivery, typically by intravenous administration, would be expected to have a broader therapeutic effect, but is also associated with an increase in side effects and toxicity.
17
15
18
].
19
20
].

Gene transfer vectors
Gene transfer vectors can be broadly categorized into two groups: viral and non-viral vectors. In general, viral vectors tend to provide for longer-term gene expression but often come with additional safety concerns, ranging from fears of generating replication competent virus during vector production, random insertion of the transgene into the genome following treatment, or development of a harmful immune response.
Plasmid DNA
21
23
]. These limitations make it unlikely that local delivery of plasmid DNA in the joint will be successful.
24
25
26
27
28
31
32
33
34
35
36
].

Other non-viral vectors
Mycobacterium tuberculosis
37
38
].
39
]. There are several different viral vectors that have been examined for use in gene transfer for arthritis, including adenovirus, retrovirus, adeno-associated virus (AAV), and lentivirus, each with their respective advantages and disadvantages.

Adenovirus
40
41
42
]. This would allow expression of the transgene during active disease, but expression would turn off once inflammation was brought under control.

Retrovirus
43
18
44
45
43
].

Lentivirus
38
46
47
48
49
50
].

AAV
v
5
51
52
54
55
56
57
].
51
58
59
].
60
61
62
63
64
65
66
].
67
]. Targeted Genetics Corporation (Seattle, WA) is currently conducting a phase I clinical trial (13G01; identifier NCT00126724) to assess the safety of using an AAV2 vector to deliver a soluble TNF receptor-Fc fusion gene in RA.


Gene transfer strategies
IL-1β inhibition
7
60
13
18
17
].
26
68
69
70
12
15
71
].

TNF-α inhibition
24
72
].
25
73
74
62
75
].
76
77
21
13
]. The above animal model data has led to the initiation of a phase I clinical trial using AAV vectors to deliver soluble TNF Receptor:Fc fusion protein (Targeted Genetics Corporation).

IL-18 inhibition
78
].

Immune deviation
79
80
81
]. Regardless of the exact mechanism, several strategies aimed at immune deviation have been successful in animal models of arthritis and are outlined below.
2
82
83
84
].
2
85
86
86
87
88
63
64
29
89
90
92
93
94
95
].
31
35
34
14
96
97
30
65
].
98
27
99
].
100
101
].

Promoting apoptosis
102
103
104
].
105
106
107
108
109
].

Anti-angiogenesis
110
111
112
113
49
66
48
114
115
116
117
118
].

Targeting matrix degradation enzymes
119
120
32
121
].

Targeting NFκB
122
123
124
].

Other strategies
INK4A
Cip1
28
33
125
136
1
Table 1
Summary of vectors and genes used in animal models of arthritis

 
Adenovirus
AAV
Retrovirus
Lentivirus
Plasmid DNA


Genes demonstrated to successfully treat arthritis in various animal models
INK4A
CIP1
, prothymosin-α, VEGF receptor I, Tie2 soluble receptor, FADD, FasL, SOCS3, urokinase plasminogen inhibitor, TIMP-1, TIMP-3, Thromobospondin-1, dominant negative NFκB inhibitor
IL-1ra, sTNFR-Ig, sTNFRI, sTNFR:Fc fusion protein, IL-4, IL-10, angiostatin, IKKβ
IL-1ra, sTNFRI variants, IL-4, TGF-β, angiostatin, soluble complement receptor I, superoxide dismutase, catalase
Angiostatin, endostatin
IL-1ra, sTNFRI receptor variants, sTNFR:Fc fusion protein, sTNFRII, TGF-β, IL-4, IL-10, vIL-10, soluble complement receptor I, TIMP-4, fibronectin peptide, sIL-1RAcP







Safety concerns
137
44
]. Lentiviral vectors may have this potential as well as sharing a similar mechanism, although this has never been demonstrated in clinical studies. More recently, in July of 2007, Jolee Mohr, a patient enrolled in Targeted Genetics’ clinical trial for rheumatoid arthritis using AAV vectors, died several weeks following her second injection of the experimental treatment. The trial is currently suspended, and although the investigation into her death is still ongoing, initial results suggest she died of a systemic fungal infection that may be unrelated to the injected virus. This case and the final results of the investigation are likely to have a large impact on the future of gene therapy trials in the United States, as AAV has been heralded as one of the most promising vectors in the field, precisely because it has, until now, failed to reveal significant safety concerns in previous studies.

Future of gene therapy for arthritis
Much progress has been made in the past several years in the use of gene therapy for the treatment of arthritis. However, there are many obstacles that must be overcome in order for it to become a viable treatment option. Future studies will need to address improving targeted delivery of vectors, regulating transgene expression, obtaining long-term transgene expression, and improving the safety and efficacy of the vectors already in use before gene therapy becomes a viable clinical therapy for arthritis.
Even in light of the recent setback in clinical trials utilizing AAV vectors, the authors believe that the future of gene transfer for arthritis will rely heavily upon this vector. Once the safety issues have been clarified, these trials can hopefully move forward. Presently, AAV would seem to be the viral vector that has the best profile in terms of safety, efficacy, and level and length of transgene expression. Alternatively, strategies using siRNA technology or preventing the dysregulation of Th17 cells would appear to be emerging as treatment strategies that may one day outperform the current standards of care for rheumatoid arthritis.


References
1.
Alamanos
Y

Drosos
AA.


Epidemiology of adult rheumatoid arthritis
Autoimmun Rev
2005
4
3
130
6
10.1016/j.autrev.2004.09.002

15823498


2.
Pollard
L

Choy
EH

Scott
DL.


The consequences of rheumatoid arthritis: quality of life measures in the individual patient
Clin Exp Rheumatol
2005
23
5 Suppl 39
S43
52

16273784


3.
Fautrel
B

Guillemin
F.


Cost of illness studies in rheumatic diseases
Curr Opin Rheumatol
2002
14
2
121
6
10.1097/00002281-200203000-00008

11845016


4.
Firestein
GS.


Evolving concepts of rheumatoid arthritis
Nature
2003
423
6937
356
61
10.1038/nature01661

12748655


5.
Weyand
CM.


New insights into the pathogenesis of rheumatoid arthritis
Rheumatology (Oxford)
2000
39
Suppl 1
3
8

11001373


6.
Goldring
SR.


Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
Rheumatology (Oxford)
2003
42
Suppl 2
ii11
6

12817090


7.
Kay
J

Calabrese
L.


The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Rheumatology (Oxford)
2004
43
Suppl 3
iii2
9
10.1093/rheumatology/keh201

15150426


8.
Dayer
JM.


The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
Rheumatology (Oxford)
2003
42
Suppl 2
ii3
10

12817089


9.
Koch
AE

Kunkel
SL

Strieter
RM.


Cytokines in rheumatoid arthritis
J Investig Med
1995
43
1
28
38

7719757


10.
Smolen
JS

Steiner
G.


Therapeutic strategies for rheumatoid arthritis
Nat Rev Drug Discov
2003
2
6
473
88
10.1038/nrd1109

12776222


11.
Olsen
NJ

Stein
CM.


New drugs for rheumatoid arthritis
N Engl J Med
2004
350
21
2167
79
10.1056/NEJMra032906

15152062


12.
Bakker
AC

Joosten
LA

Arntz
OJ

Helsen
MM

Bendele
AM

Loo
FA



Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee
Arthritis Rheum
1997
40
5
893
900
10.1002/art.1780400517

9153551


13.
Ghivizzani
SC

Lechman
ER

Kang
R

Tio
C

Kolls
J

Evans
CH



Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects
Proc Natl Acad Sci USA
1998
95
8
4613
8
10.1073/pnas.95.8.4613

9539786


14.
Ma
Y

Thornton
S

Duwel
LE

Boivin
GP

Giannini
EH

Leiden
JM



Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer
J Immunol
1998
161
3
1516
24

9686619


15.
Kim
SH

Lechman
ER

Kim
S

Nash
J

Oligino
TJ

Robbins
PD.


Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis
Mol Ther
2002
6
5
591
600
10.1016/S1525-0016(02)90711-2

12409257


16.
Lechman
ER

Keravala
A

Nash
J

Kim
SH

Mi
Z

Robbins
PD.


The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen
Gene Ther
2003
10
24
2029
35
10.1038/sj.gt.3302109

14566362


17.
Evans
CH

Robbins
PD

Ghivizzani
SC

Wasko
MC

Tomaino
MM

Kang
R



Gene transfer to human joints: progress toward a gene therapy of arthritis
Proc Natl Acad Sci USA
2005
102
24
8698
703
10.1073/pnas.0502854102

15939878


18.
Otani
K

Nita
I

Macaulay
W

Georgescu
HI

Robbins
PD

Evans
CH.


Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
J Immunol
1996
156
9
3558
62

8617986


19.
Mor
A

Abramson
SB

Pillinger
MH.


The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction
Clin Immunol
2005
115
2
118
28
10.1016/j.clim.2004.12.009

15885632


20.
Pap
T

Gay
RE

Muller-Ladner
U

Gay
S.


Ex vivo gene transfer in the years to come
Arthritis Res
2002
4
1
10
2
10.1186/ar377

11879532


21.
Chan
JM

Villarreal
G

Jin
WW

Stepan
T

Burstein
H

Wahl
SM.


Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product
Mol Ther
2002
6
6
727
36
10.1006/mthe.2002.0808

12498769


22.
Ohashi
S

Kubo
T

Kishida
T

Ikeda
T

Takahashi
K

Arai
Y



Successful genetic transduction in vivo into synovium by means of electroporation
Biochem Biophys Res Commun
2002
293
5
1530
5
10.1016/S0006-291X(02)00386-8

12054690


23.
Yovandich
J

O’Malley
B

Sikes
M

Ledley
FD.


Gene transfer to synovial cells by intra-articular administration of plasmid DNA
Hum Gene Ther
1995
6
5
603
10

7578397


24.
Bloquel
C

Bessis
N

Boissier
MC

Scherman
D

Bigey
P.


Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants
Hum Gene Ther
2004
15
2
189
201
10.1089/104303404772679995

14975191


25.
Kim
JM

Ho
SH

Hahn
W

Jeong
JG

Park
EJ

Lee
HJ



Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein
Gene Ther
2003
10
15
1216
24
10.1038/sj.gt.3301985

12858186


26.
Kim
JM

Jeong
JG

Ho
SH

Hahn
W

Park
EJ

Kim
S



Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist
Gene Ther
2003
10
18
1543
50
10.1038/sj.gt.3302042

12907945


27.
Song
XY

Gu
M

Jin
WW

Klinman
DM

Wahl
SM.


Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model
J Clin Invest
1998
101
12
2615
21

9637694


28.
Dreja
H

Annenkov
A

Chernajovsky
Y.


Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis
Arthritis Rheum
2000
43
8
1698
709
10.1002/1529-0131(200008)43:8<1698::AID-ANR5>3.0.CO;2-8

10943859


29.
Ho
SH

Hahn
W

Lee
HJ

Kim
DS

Jeong
JG

Kim
S



Protection against collagen-induced arthritis by electrotransfer of an expression plasmid for the interleukin-4
Biochem Biophys Res Commun
2004
321
4
759
66
10.1016/j.bbrc.2004.07.028

15358092


30.
Kuroda
T

Maruyama
H

Shimotori
M

Higuchi
N

Kameda
S

Tahara
H



Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice
J Rheumatol
2006
33
3
455
62

16511914


31.
Saidenberg-Kermanac’h
N

Bessis
N

Deleuze
V

Bloquel
C

Bureau
M

Scherman
D



Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis
J Gene Med
2003
5
2
164
71
10.1002/jgm.321

12539154


32.
Celiker
MY

Ramamurthy
N

Xu
JW

Wang
M

Jiang
Y

Greenwald
R



Inhibition of adjuvant-induced arthritis by systemic tissue inhibitor of metalloproteinases 4 gene delivery
Arthritis Rheum
2002
46
12
3361
8
10.1002/art.10648

12483743


33.
Imagawa
T

Watanabe
S

Katakura
S

Boivin
GP

Hirsch
R.


Gene transfer of a fibronectin peptide inhibits leukocyte recruitment and suppresses inflammation in mouse collagen-induced arthritis
Arthritis Rheum
2002
46
4
1102
8
10.1002/art.10188

11953990


34.
Fellowes
R

Etheridge
CJ

Coade
S

Cooper
RG

Stewart
L

Miller
AD



Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery
Gene Ther
2000
7
11
967
77
10.1038/sj.gt.3301165

10849557


35.
Miyata
M

Sasajima
T

Sato
H

Saito
A

Saito
A

Iriswa
A



Suppression of collagen induced arthritis in mice utilizing plasmid DNA encoding interleukin 10
J Rheumatol
2000
27
7
1601
5

10914840


36.
Zhang
X

Yu
C

Xushi

Zhang
C

Tang
T

Dai
K.


Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo
Biochem Biophys Res Commun
2006
341
1
202
8
10.1016/j.bbrc.2005.12.171

16413501


37.
Adriaansen
J

Vervoordeldonk
MJ

Vanderbyl
S

Jong
G

Tak
PP.


A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation
J Gene Med
2006
8
1
63
71
10.1002/jgm.810

16038012


38.
Barquinero
J

Eixarch
H

Perez-Melgosa
M.


Retroviral vectors: new applications for an old tool
Gene Ther
2004
11
Suppl 1
S3
9
10.1038/sj.gt.3302363

15454951


39.
Nita
I

Ghivizzani
SC

Galea-Lauri
J

Bandara
G

Georgescu
HI

Robbins
PD



Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo
Arthritis Rheum
1996
39
5
820
8
10.1002/art.1780390515

8639179


40.
Goossens
PH

Havenga
MJ

Pieterman
E

Lemckert
AA

Breedveld
FC

Bout
A



Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber
Arthritis Rheum
2001
44
3
570
7
10.1002/1529-0131(200103)44:3<570::AID-ANR105>3.0.CO;2-Y

11263771


41.
Toh
ML

Hong
SS

Loo
F

Franqueville
L

Lindholm
L

Berg
W



Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)- and non-RGD-binding integrins
J Immunol
2005
175
11
7687
98

16301679


42.
Loo
FA

Hooge
AS

Smeets
RL

Bakker
AC

Bennink
MB

Arntz
OJ



An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint
Gene Ther
2004
11
7
581
90
10.1038/sj.gt.3302182

14973543


43.
Anson
DS.


The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery
Genet Vaccines Ther
2004
2
1
9
10.1186/1479-0556-2-9

15310406


44.
Hacein-Bey-Abina
S

Kalle
C

Schmidt
M

McCormack
MP

Wulffraat
N

Leboulch
P



LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
Science
2003
302
5644
415
9
10.1126/science.1088547

14564000


45.
Kaiser
J.


Gene therapy. Panel urges limits on X-SCID trials
Science
2005
307
5715
1544
5
10.1126/science.307.5715.1544a

15761128


46.
Sauter
SL

Gasmi
M.


FIV vector systems
Somat Cell Mol Genet
2001
26
1–6
99
129
10.1023/A:1021078714105

12465464


47.
Lin
YL

Noel
D

Mettling
C

Reant
B

Clot
J

Jorgensen
C



Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis
Hum Gene Ther
2004
15
6
588
96
10.1089/104303404323142033

15212717


48.
Yin
G

Liu
W

An
P

Li
P

Ding
I

Planelles
V



Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis
Mol Ther
2002
5
5 Pt 1
547
54
10.1006/mthe.2002.0590

11991745


49.
Kato
K

Miyake
K

Igarashi
T

Yoshino
S

Shimada
T.


Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice
Rheumatol Int
2005
25
7
522
9
10.1007/s00296-004-0476-7

15205911


50.
Gouze
E

Pawliuk
R

Pilapil
C

Gouze
JN

Fleet
C

Palmer
GD



In vivo gene delivery to synovium by lentiviral vectors
Mol Ther
2002
5
4
397
404
10.1006/mthe.2002.0562

11945066


51.
Lai
CM

Lai
YK

Rakoczy
PE.


Adenovirus and adeno-associated virus vectors
DNA Cell Biol
2002
21
12
895
913
10.1089/104454902762053855

12573049


52.
Bartlett
JS

Wilcher
R

Samulski
RJ.


Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
J Virol
2000
74
6
2777
85
10.1128/JVI.74.6.2777-2785.2000

10684294


53.
Douar
AM

Poulard
K

Stockholm
D

Danos
O.


Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation
J Virol
2001
75
4
1824
33
10.1128/JVI.75.4.1824-1833.2001

11160681


54.
Sanlioglu
AD

Karacay
B

Benson
PK

Engelhardt
JF

Sanlioglu
S.


Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction
Virus Res
2004
104
1
51
9
10.1016/j.virusres.2004.03.002

15177892


55.
Hansen
J

Qing
K

Srivastava
A.


Infection of purified nuclei by adeno-associated virus 2
Mol Ther
2001
4
4
289
96
10.1006/mthe.2001.0457

11592830


56.
Ferrari
FK

Samulski
T

Shenk
T

Samulski
RJ.


Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors
J Virol
1996
70
5
3227
34

8627803


57.
Fisher
KJ

Gao
GP

Weitzman
MD

DeMatteo
R

Burda
JF

Wilson
JM.


Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
J Virol
1996
70
1
520
32

8523565


58.
Ponnazhagan
S

Erikson
D

Kearns
WG

Zhou
SZ

Nahreini
P

Wang
XS



Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells
Hum Gene Ther
1997
8
3
275
84

9048194


59.
Wang
Z

Ma
HI

Li
J

Sun
L

Zhang
J

Xiao
X.


Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo
Gene Ther
2003
10
26
2105
11
10.1038/sj.gt.3302133

14625564


60.
Pan
RY

Chen
SL

Xiao
X

Liu
DW

Peng
HJ

Tsao
YP.


Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist
Arthritis Rheum
2000
43
2
289
97
10.1002/1529-0131(200002)43:2<289::AID-ANR8>3.0.CO;2-H

10693868


61.
Jennings
K

Miyamae
T

Traister
R

Marinov
A

Katakura
S

Sowders
D



Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo
Mol Ther
2005
11
4
600
7
10.1016/j.ymthe.2004.10.020

15771962


62.
Zhang
HG

Xie
J

Yang
P

Wang
Y

Xu
L

Liu
D



Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis
Hum Gene Ther
2000
11
17
2431
42
10.1089/104303400750038525

11096446


63.
Cottard
V

Mulleman
D

Bouille
P

Mezzina
M

Boissier
MC

Bessis
N.


Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis
Gene Ther
2000
7
22
1930
9
10.1038/sj.gt.3301324

11127581


64.
Watanabe
S

Imagawa
T

Boivin
GP

Gao
G

Wilson
JM

Hirsch
R.


Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium
Mol Ther
2000
2
2
147
52
10.1006/mthe.2000.0111

10947942


65.
Apparailly
F

Millet
V

Noel
D

Jacquet
C

Sany
J

Jorgensen
C.


Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis
Hum Gene Ther
2002
13
10
1179
88
10.1089/104303402320138961

12133271


66.
Takahashi
H

Kato
K

Miyake
K

Hirai
Y

Yoshino
S

Shimada
T.


Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice
Clin Exp Rheumatol
2005
23
4
455
61

16095112


67.
Conlon
TJ

Flotte
TR.


Recombinant adeno-associated virus vectors for gene therapy
Expert Opin Biol Ther
2004
4
7
1093
101
10.1517/14712598.4.7.1093

15268676


68.
Jeong
JG

Kim
JM

Ho
SH

Hahn
W

Yu
SS

Kim
S.


Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis
J Gene Med
2004
6
10
1125
33
10.1002/jgm.599

15452879


69.
Makarov
SS

Olsen
JC

Johnston
WN

Anderle
SK

Brown
RR

Baldwin
AS



Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA
Proc Natl Acad Sci USA
1996
93
1
402
6
10.1073/pnas.93.1.402

8552648


70.
Muller-Ladner
U

Roberts
CR

Franklin
BN

Gay
RE

Robbins
PD

Evans
CH



Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective
J Immunol
1997
158
7
3492
8

9120311


71.
Smeets
RL

Loo
FA

Joosten
LA

Arntz
OJ

Bennink
MB

Loesberg
WA



Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis
Arthritis Rheum
2003
48
10
2949
58
10.1002/art.11234

14558102


72.
Mukherjee
P

Wu
B

Mayton
L

Kim
SH

Robbins
PD

Wooley
PH.


TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis
Ann Rheum Dis
2003
62
8
707
14
10.1136/ard.62.8.707

12860724


73.
Gould
DJ

Bright
C

Chernajovsky
Y.


Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline--regulated plasmid
Arthritis Res Ther
2004
6
2
R103
13
10.1186/ar1036

15059273


74.
Gould
D

Yousaf
N

Fatah
R

Subang
MC

Chernajovsky
Y.


Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis
Arthritis Res Ther
2007
9
1
R7
10.1186/ar2113

17254348


75.
Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 2007.

76.
Chernajovsky
Y

Adams
G

Podhajcer
OL

Mueller
GM

Robbins
PD

Feldmann
M.


Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor
Gene Ther
1995
2
10
731
5

8750012


77.
Mageed
RA

Adams
G

Woodrow
D

Podhajcer
OL

Chernajovsky
Y.


Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor
Gene Ther
1998
5
12
1584
92
10.1038/sj.gt.3300785

10023437


78.
Smeets
RL

Loo
FA

Arntz
OJ

Bennink
MB

Joosten
LA

Berg
WB.


Adenoviral delivery of IL-18-binding protein C ameliorates collagen-induced arthritis in mice
Gene Ther
2003
10
12
1004
11
10.1038/sj.gt.3301986

12776157


79.
Harrington
LE

Hatton
RD

Mangan
PR

Turner
H

Murphy
TL

Murphy
KM



Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
Nat Immunol
2005
6
11
1123
32
10.1038/ni1254

16200070


80.
Lubberts
E

Koenders
MI

Oppers-Walgreen
B

Bersselaar
L

Coenen-de Roo
CJ

Joosten
LA



Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion
Arthritis Rheum
2004
50
2
650
9
10.1002/art.20001

14872510


81.
Bettelli
E

Carrier
Y

Gao
W

Korn
T

Strom
TB

Oukka
M



Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Nature
2006
441
7090
235
8
10.1038/nature04753

16648838


82.
Woods
JM

Katschke
KJ

Tokuhira
M

Kurata
H

Arai
KI

Campbell
PL



Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium
J Immunol
2000
165
5
2755
63

10946307


83.
Woods
JM

Amin
MA

Katschke
KJ

Volin
MV

Ruth
JH

Connors
MA



Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis
Hum Gene Ther
2002
13
3
381
93
10.1089/10430340252792512

11860705


84.
Nabbe
KC

Lent
PL

Holthuysen
AE

Sloetjes
AW

Koch
AE

Radstake
TR



Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation
Arthritis Res Ther
2005
7
2
R392
401
10.1186/ar1502

15743487


85.
Woods
JM

Tokuhira
M

Berry
JC

Katschke
KJ

Kurata
H

Damergis
JA



Interleukin-4 adenoviral gene therapy reduces production of inflammatory cytokines and prostaglandin E2 by rheumatoid arthritis synovium ex vivo.
J Investig Med
1999
47
6
285
92

10431483


86.
Lubberts
E

Joosten
LA

Bersselaar
L

Helsen
MM

Bakker
AC

Meurs
JB



Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction
J Immunol
1999
163
8
4546
56

10510398


87.
Lubberts
E

Joosten
LA

Chabaud
M

Bersselaar
L

Oppers
B

Coenen-De Roo
CJ



IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
J Clin Invest
2000
105
12
1697
710

10862785


88.
Kim
SH

Evans
CH

Kim
S

Oligino
T

Ghivizzani
SC

Robbins
PD.


Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4.
Arthritis Res
2000
2
4
293
302
10.1186/ar104

11056670


89.
Kageyama
Y

Koide
Y

Uchijima
M

Nagata
T

Yoshida
A

Taiki
A



Plasmid encoding interleukin-4 in the amelioration of murine collagen-induced arthritis.
Arthritis Rheum
2004
50
3
968
75
10.1002/art.20107

15022341


90.
Boyle
DL

Nguyen
KH

Zhuang
S

Shi
Y

McCormack
JE

Chada
S



Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity
Gene Ther
1999
6
12
1911
8
10.1038/sj.gt.3301049

10637442


91.
Woods
JM

Katschke
KJ

Volin
MV

Ruth
JH

Woodruff
DC

Amin
MA



IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis
J Immunol
2001
166
2
1214
22

11145704


92.
Haas
CS

Amin
MA

Allen
BB

Ruth
JH

Haines
GK

Woods
JM



Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis
Arthritis Rheum
2006
54
8
2402
14
10.1002/art.22034

16869003


93.
Bessis
N

Cottard
V

Saidenberg-Kermanac’h
N

Lemeiter
D

Fournier
C

Boissier
MC.


Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis
J Gene Med
2002
4
3
300
7
10.1002/jgm.275

12112647


94.
Saidenberg-Kermanac’h
N

Bessis
N

Lemeiter
D

Vernejoul
MC

Boissier
MC

Cohen-Solal
M.


Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis
J Clin Immunol
2004
24
4
370
8
10.1023/B:JOCI.0000029116.12371.bf

15163893


95.
Guery
L

Chiocchia
G

Batteux
F

Boissier
MC

Fournier
C.


Collagen II-pulsed antigen-presenting cells genetically modified to secrete IL-4 down-regulate collagen-induced arthritis
Gene Ther
2001
8
24
1855
62
10.1038/sj.gt.3301613

11821939


96.
Apparailly
F

Verwaerde
C

Jacquet
C

Auriault
C

Sany
J

Jorgensen
C.


Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis
J Immunol
1998
160
11
5213
20

9605116


97.
Whalen
JD

Lechman
EL

Carlos
CA

Weiss
K

Kovesdi
I

Glorioso
JC



Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws
J Immunol
1999
162
6
3625
32

10092823


98.
Chernajovsky
Y

Adams
G

Triantaphyllopoulos
K

Ledda
MF

Podhajcer
OL.


Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model
Gene Ther
1997
4
6
553
9
10.1038/sj.gt.3300436

9231071


99.
Mi
Z

Ghivizzani
SC

Lechman
E

Glorioso
JC

Evans
CH

Robbins
PD.


Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees
Arthritis Res Ther
2003
5
3
R132
9
10.1186/ar745

12723985


100.
Quattrocchi
E

Dallman
MJ

Feldmann
M.


Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis
Arthritis Rheum
2000
43
8
1688
97
10.1002/1529-0131(200008)43:8<1688::AID-ANR4>3.0.CO;2-C

10943858


101.
Ijima
K

Murakami
M

Okamoto
H

Inobe
M

Chikuma
S

Saito
I



Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis
Hum Gene Ther
2001
12
9
1063
77
10.1089/104303401750214285

11399228


102.
Yao
Q

Wang
S

Gambotto
A

Glorioso
JC

Evans
CH

Robbins
PD



Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium
Gene Ther
2003
10
12
1055
60
10.1038/sj.gt.3301881

12776164


103.
Liu
Z

Xu
X

Hsu
HC

Tousson
A

Yang
PA

Wu
Q



CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis
J Clin Invest
2003
112
9
1332
41
10.1172/JCI200319209

14597760


104.
Terzioglu
E

Bisgin
A

Sanlioglu
AD

Ulker
M

Yazisiz
V

Tuzuner
S



Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis
Rheumatology (Oxford)
2007
46
5
783
9
10.1093/rheumatology/kel448

17309888


105.
Zhang
H

Yang
Y

Horton
JL

Samoilova
EB

Judge
TA

Turka
LA



Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer
J Clin Invest
1997
100
8
1951
7

9329958


106.
Okamoto
K

Asahara
H

Kobayashi
T

Matsuno
H

Hasunuma
T

Kobata
T



Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer
Gene Ther
1998
5
3
331
8
10.1038/sj.gt.3300597

9614552


107.
Zhang
H

Gao
G

Clayburne
G

Schumacher
HR.


Elimination of rheumatoid synovium in situ using a Fas ligand ‘gene scalpel’
Arthritis Res Ther
2005
7
6
R1235
43
10.1186/ar1811

16277676


108.
Kim
SH

Kim
S

Oligino
TJ

Robbins
PD.


Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL
Mol Ther
2002
6
5
584
90
10.1016/S1525-0016(02)90712-4

12409256


109.
Kobayashi
T

Okamoto
K

Kobata
T

Hasunuma
T

Kato
T

Hamada
H



Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes
Gene Ther
2000
7
6
527
33
10.1038/sj.gt.3301127

10757027


110.
Colville-Nash
PR

Scott
DL.


Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications
Ann Rheum Dis
1992
51
7
919
25

1378718


111.
Kimball
ES

Gross
JL.


Angiogenesis in pannus formation
Agents Actions
1991
34
3–4
329
31
10.1007/BF01988724

1725688


112.
Gerlag
DM

Borges
E

Tak
PP

Ellerby
HM

Bredesen
DE

Pasqualini
R



Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature
Arthritis Res
2001
3
6
357
61
10.1186/ar327

11714389


113.
Kim
JM

Ho
SH

Park
EJ

Hahn
W

Cho
H

Jeong
JG



Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis
Arthritis Rheum
2002
46
3
793
801
10.1002/art.10113

11920417


114.
Chen
Y

Donnelly
E

Kobayashi
H

Debusk
LM

Lin
PC.


Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction
Arthritis Rheum
2005
52
5
1585
94
10.1002/art.21016

15880817


115.
Afuwape
AO

Feldmann
M

Paleolog
EM.


Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis
Gene Ther
2003
10
23
1950
60
10.1038/sj.gt.3302104

14528319


116.
Jou
IM

Shiau
AL

Chen
SY

Wang
CR

Shieh
DB

Tsai
CS



Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis
Arthritis Rheum
2005
52
1
339
44
10.1002/art.20746

15641039


117.
Park
YW

Kang
YM

Butterfield
J

Detmar
M

Goronzy
JJ

Weyand
CM.


Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis
Am J Pathol
2004
165
6
2087
98

15579451


118.
Apparailly
F

Bouquet
C

Millet
V

Noel
D

Jacquet
C

Opolon
P



Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis
Gene Ther
2002
9
3
192
200
10.1038/sj.gt.3301628

11859422


119.
Rutkauskaite
E

Volkmer
D

Shigeyama
Y

Schedel
J

Pap
G

Muller-Ladner
U



Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts
Arthritis Rheum
2005
52
7
2010
4
10.1002/art.21156

15986375


120.
Rutkauskaite
E

Zacharias
W

Schedel
J

Muller-Ladner
U

Mawrin
C

Seemayer
CA



Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts
Arthritis Rheum
2004
50
5
1448
56
10.1002/art.20186

15146414


121.
Laan
WH

Quax
PH

Seemayer
CA

Huisman
LG

Pieterman
EJ

Grimbergen
JM



Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3
Gene Ther
2003
10
3
234
42
10.1038/sj.gt.3301871

12571631


122.
Tomita
T

Takeuchi
E

Tomita
N

Morishita
R

Kaneko
M

Yamamoto
K



Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy
Arthritis Rheum
1999
42
12
2532
42
10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2

10615998


123.
Zhang
HG

Huang
N

Liu
D

Bilbao
L

Zhang
X

Yang
P



Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts
Arthritis Rheum
2000
43
5
1094
105
10.1002/1529-0131(200005)43:5<1094::AID-ANR20>3.0.CO;2-V

10817564


124.
Tas
SW

Adriaansen
J

Hajji
N

Bakker
AC

Firestein
GS

Vervoordeldonk
MJ



Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5
Hum Gene Ther
2006
17
8
821
32
10.1089/hum.2006.17.821

16942442


125.
Shouda
T

Yoshida
T

Hanada
T

Wakioka
T

Oishi
M

Miyoshi
K



Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis
J Clin Invest
2001
108
12
1781
8
10.1172/JCI200113568

11748261


126.
Takayanagi
H

Juji
T

Miyazaki
T

Iizuka
H

Takahashi
T

Isshiki
M



Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
J Clin Invest
1999
104
2
137
46

10411542


127.
Yamamoto
A

Fukuda
A

Seto
H

Miyazaki
T

Kadono
Y

Sawada
Y



Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts
Arthritis Rheum
2003
48
9
2682
92
10.1002/art.11214

13130489


128.
Rabinovich
GA

Daly
G

Dreja
H

Tailor
H

Riera
CM

Hirabayashi
J



Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis
J Exp Med
1999
190
3
385
98
10.1084/jem.190.3.385

10430627


129.
Schedel
J

Seemayer
CA

Pap
T

Neidhart
M

Kuchen
S

Michel
BA



Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis
Gene Ther
2004
11
13
1040
7
10.1038/sj.gt.3302265

15164093


130.
Nonomura
Y

Kohsaka
H

Nasu
K

Terada
Y

Ikeda
M

Miyasaka
N.


Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints
Int Immunol
2001
13
6
723
31
10.1093/intimm/13.6.723

11369699


131.
Taniguchi
K

Kohsaka
H

Inoue
N

Terada
Y

Ito
H

Hirokawa
K



Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis
Nat Med
1999
5
7
760
7
10.1038/10480

10395320


132.
Triantaphyllopoulos
KA

Williams
RO

Tailor
H

Chernajovsky
Y.


Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy
Arthritis Rheum
1999
42
1
90
9
10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A

9920019


133.
Dai
L

Claxson
A

Marklund
SL

Feakins
R

Yousaf
N

Chernajovsky
Y



Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes
Gene Ther
2003
10
7
550
8
10.1038/sj.gt.3301916

12646860


134.
Iyama
S

Okamoto
T

Sato
T

Yamauchi
N

Sato
Y

Sasaki
K



Treatment of murine collagen-induced arthritis by ex vivo extracellular superoxide dismutase gene transfer
Arthritis Rheum
2001
44
9
2160
7
10.1002/1529-0131(200109)44:9<2160::AID-ART369>3.0.CO;2-0

11592381


135.
Adriaansen
J

Fallaux
FJ

Cortie
CJ

Vervoordeldonk
MJ

Tak
PP.


Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats
J Gen Virol
2007
88
Pt 6
1717
21
10.1099/vir.0.82603-0

17485531


136.
Shiau
AL

Chen
SY

Chang
MY

Su
CH

Chung
SY

Yo
YT



Prothymosin alpha lacking the nuclear localization signal as an effective gene therapeutic strategy in collagen-induced arthritis
J Immunol
2007
178
7
4688
94

17372028


137.
Raper
SE

Chirmule
N

Lee
FS

Wivel
NA

Bagg
A

Gao
GP



Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer
Mol Genet Metab
2003
80
1–2
148
58
10.1016/j.ymgme.2003.08.016

14567964





